Craig-Hallum initiated coverage of PMV Pharmaceuticals with a Buy rating and $6 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP:
- PMV Pharmaceuticals sees cash runway to end of 2026
- PMV Pharmaceuticals reports Q1 EPS (30c), consensus (36c)
- PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
- PMV Pharmaceuticals initiated with a Buy at Jefferies
- PMV Pharmaceuticals announces first patient dosed in Phase 2 PYNNACLE trial